EXAS Stock Analysis: Buy, Sell, or Hold?
EXAS - Exact Sciences Corp
$102.34
0.04 (0.04%)
▲
BUY
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Feb 18, 2026
17d
Get Alerted When EXAS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: EXAS shows positive signals but monitor for confirmation. Market pricing in 0.8% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: EXAS shows positive signals but monitor for confirmation. Market pricing in 0.8% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$54.42
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$33.79
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: EXAS is currently trading at $102.34, which is considered slightly high relative to its 30-day fair value range of $101.71 to $102.37. The stock's valuation (Forward PE: 91.5) is in line with its historical norms (89.4). At these levels, the market is pricing in 0.8% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, EXAS is in a strong uptrend. The price is currently testing key support at $102.00. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, EXAS is in a strong uptrend. The price is currently testing key support at $102.00. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Fair Price Range
$101.71 -
$102.37
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.4%
Protect Your Profits
EXAS is technically overbought (RSI 73). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($105.81)
- NEUTRAL: Market pricing in 0.8% annual earnings growth - fairly valued
Fair Price Analysis
30-Day Fair Range
$101.71 -
$102.37
Current vs Fair Value
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$102.00
Resistance Level
$102.66
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
91.51
Wall Street Target
$105.81
(+3.4%)
Revenue Growth (YoY)
20.1%
Profit Margin
-32.0%
Valuation Premium vs History
+0.8% premium
PE vs Historical
91.5 vs 89.4
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.8%
(market-implied from PE analysis)
1-Year Target
$103.12
(+1%)
2-Year Target
$103.94
(+2%)
3-Year Target
$104.77
(+2%)
3-Yr Target (if PE normalizes)
(PE: 92→89)
PE COMPRESSION
$102.36
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 91.5, Growth: 230.6%)
$345.26
(+238%)
Base:
(SPY PE: 22.3, Growth: 230.6%)
$84.14
(-18%)
Bear:
(PE: 19.0, Growth: 230.6%)
$71.52
(-30%)
Last updated: January 30, 2026 11:56 PM ET
Data refreshes hourly during market hours. Next update: 12:56 AM
Data refreshes hourly during market hours. Next update: 12:56 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EXAS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
James Edward Doyle
SELL
2000 shares
2025-10-09
James Edward Doyle
SELL
1485 shares
2025-08-13
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher Scientific… |
STRONG BUY
31 analysts |
$653 | 47 HOLD |
|
GH
Guardant Health Inc |
STRONG BUY
24 analysts |
$121 | 62 BUY |
|
DHR
Danaher Corporation |
STRONG BUY
26 analysts |
$263 | 47 HOLD |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$257 | 58 HOLD |
|
IQV
IQVIA Holdings Inc |
BUY
23 analysts |
$261 | 59 HOLD |
Advanced EXAS Option Strategies
Professional options setups generated by AI based on today's EXAS price and gamma walls.
